Plasma laudanosine levels in patients given atracurium during liver transplantation

R. G. Lawhead, M. Matsumi, K Reed Peters, D. F. Landers, G. L. Becker, R. A. Earl

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Atracurium, a nondepolarizing muscle relaxant, does not depend on the liver for clearance, but its principal metabolite, laudanosine, is eliminated primarily by the liver and is potentially neurotoxic. We measured atracurium and laudanosine levels in 15 adult patients during the three stages of liver transplantation to assess the effect of major impairment of liver function. Atracurium was given in a bolus dose of 0.5 mg/kg followed by continuous infusion at a rate adjusted to maintain 95-99% of total neuromuscular block, as judged by train of four response to facial nerve stimulation. Atracurium levels remained constant at 1.4-1.8 μg/mL during the 180-min preanhepatic and 75-min anhepatic stages but decreased to a mean of 1.0 μg/mL by the end of the 180-min postanhepatic stage. In contrast, laudanosine levels increased during each stage, being 0.40 ± 0.18, 0.50 ± 0.22, and 0.43 ± 0.16 μg/mL after the preanhepatic, anhepatic, and postanhepatic stages, respectively. The highest individual value recorded was 1.02 μg/mL. We conclude that, despite increases in laudanosine levels during each stage of liver transplantation in patients receiving atracurium, those levels are only about one-tenth of the maximum values previously reported in humans.

Original languageEnglish (US)
Pages (from-to)569-573
Number of pages5
JournalAnesthesia and analgesia
Volume76
Issue number3
StatePublished - Jan 1 1993

Fingerprint

Atracurium
Liver Transplantation
Liver
Neuromuscular Blockade
Facial Nerve
laudanosine
Muscles

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Lawhead, R. G., Matsumi, M., Peters, K. R., Landers, D. F., Becker, G. L., & Earl, R. A. (1993). Plasma laudanosine levels in patients given atracurium during liver transplantation. Anesthesia and analgesia, 76(3), 569-573.

Plasma laudanosine levels in patients given atracurium during liver transplantation. / Lawhead, R. G.; Matsumi, M.; Peters, K Reed; Landers, D. F.; Becker, G. L.; Earl, R. A.

In: Anesthesia and analgesia, Vol. 76, No. 3, 01.01.1993, p. 569-573.

Research output: Contribution to journalArticle

Lawhead, RG, Matsumi, M, Peters, KR, Landers, DF, Becker, GL & Earl, RA 1993, 'Plasma laudanosine levels in patients given atracurium during liver transplantation', Anesthesia and analgesia, vol. 76, no. 3, pp. 569-573.
Lawhead RG, Matsumi M, Peters KR, Landers DF, Becker GL, Earl RA. Plasma laudanosine levels in patients given atracurium during liver transplantation. Anesthesia and analgesia. 1993 Jan 1;76(3):569-573.
Lawhead, R. G. ; Matsumi, M. ; Peters, K Reed ; Landers, D. F. ; Becker, G. L. ; Earl, R. A. / Plasma laudanosine levels in patients given atracurium during liver transplantation. In: Anesthesia and analgesia. 1993 ; Vol. 76, No. 3. pp. 569-573.
@article{3e19a7eea0b848aca96fe8ed8b2e296a,
title = "Plasma laudanosine levels in patients given atracurium during liver transplantation",
abstract = "Atracurium, a nondepolarizing muscle relaxant, does not depend on the liver for clearance, but its principal metabolite, laudanosine, is eliminated primarily by the liver and is potentially neurotoxic. We measured atracurium and laudanosine levels in 15 adult patients during the three stages of liver transplantation to assess the effect of major impairment of liver function. Atracurium was given in a bolus dose of 0.5 mg/kg followed by continuous infusion at a rate adjusted to maintain 95-99{\%} of total neuromuscular block, as judged by train of four response to facial nerve stimulation. Atracurium levels remained constant at 1.4-1.8 μg/mL during the 180-min preanhepatic and 75-min anhepatic stages but decreased to a mean of 1.0 μg/mL by the end of the 180-min postanhepatic stage. In contrast, laudanosine levels increased during each stage, being 0.40 ± 0.18, 0.50 ± 0.22, and 0.43 ± 0.16 μg/mL after the preanhepatic, anhepatic, and postanhepatic stages, respectively. The highest individual value recorded was 1.02 μg/mL. We conclude that, despite increases in laudanosine levels during each stage of liver transplantation in patients receiving atracurium, those levels are only about one-tenth of the maximum values previously reported in humans.",
author = "Lawhead, {R. G.} and M. Matsumi and Peters, {K Reed} and Landers, {D. F.} and Becker, {G. L.} and Earl, {R. A.}",
year = "1993",
month = "1",
day = "1",
language = "English (US)",
volume = "76",
pages = "569--573",
journal = "Anesthesia and Analgesia",
issn = "0003-2999",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Plasma laudanosine levels in patients given atracurium during liver transplantation

AU - Lawhead, R. G.

AU - Matsumi, M.

AU - Peters, K Reed

AU - Landers, D. F.

AU - Becker, G. L.

AU - Earl, R. A.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Atracurium, a nondepolarizing muscle relaxant, does not depend on the liver for clearance, but its principal metabolite, laudanosine, is eliminated primarily by the liver and is potentially neurotoxic. We measured atracurium and laudanosine levels in 15 adult patients during the three stages of liver transplantation to assess the effect of major impairment of liver function. Atracurium was given in a bolus dose of 0.5 mg/kg followed by continuous infusion at a rate adjusted to maintain 95-99% of total neuromuscular block, as judged by train of four response to facial nerve stimulation. Atracurium levels remained constant at 1.4-1.8 μg/mL during the 180-min preanhepatic and 75-min anhepatic stages but decreased to a mean of 1.0 μg/mL by the end of the 180-min postanhepatic stage. In contrast, laudanosine levels increased during each stage, being 0.40 ± 0.18, 0.50 ± 0.22, and 0.43 ± 0.16 μg/mL after the preanhepatic, anhepatic, and postanhepatic stages, respectively. The highest individual value recorded was 1.02 μg/mL. We conclude that, despite increases in laudanosine levels during each stage of liver transplantation in patients receiving atracurium, those levels are only about one-tenth of the maximum values previously reported in humans.

AB - Atracurium, a nondepolarizing muscle relaxant, does not depend on the liver for clearance, but its principal metabolite, laudanosine, is eliminated primarily by the liver and is potentially neurotoxic. We measured atracurium and laudanosine levels in 15 adult patients during the three stages of liver transplantation to assess the effect of major impairment of liver function. Atracurium was given in a bolus dose of 0.5 mg/kg followed by continuous infusion at a rate adjusted to maintain 95-99% of total neuromuscular block, as judged by train of four response to facial nerve stimulation. Atracurium levels remained constant at 1.4-1.8 μg/mL during the 180-min preanhepatic and 75-min anhepatic stages but decreased to a mean of 1.0 μg/mL by the end of the 180-min postanhepatic stage. In contrast, laudanosine levels increased during each stage, being 0.40 ± 0.18, 0.50 ± 0.22, and 0.43 ± 0.16 μg/mL after the preanhepatic, anhepatic, and postanhepatic stages, respectively. The highest individual value recorded was 1.02 μg/mL. We conclude that, despite increases in laudanosine levels during each stage of liver transplantation in patients receiving atracurium, those levels are only about one-tenth of the maximum values previously reported in humans.

UR - http://www.scopus.com/inward/record.url?scp=0027407026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027407026&partnerID=8YFLogxK

M3 - Article

VL - 76

SP - 569

EP - 573

JO - Anesthesia and Analgesia

JF - Anesthesia and Analgesia

SN - 0003-2999

IS - 3

ER -